Based on in vitro studies, ERβ ligands inhibit NRAS mutation and thus the proliferation of melanoma cells, demonstrating that ERβ activation might weaken melanoma development by preventing the PI3K/Akt pathway (163). This evidence concerns the gene ESR2 and melanoma.